Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy
Despite impressive antitumor efficacy of programmed cell death 1 (PD-1) inhibitors, this inhibition can induce mild to severe autoimmune toxicities, termed immune-related adverse events (irAEs). Yet, predictive pretreatment biomarkers for irAEs development across cancer types remain elusive. We firs...
Main Authors: | Lei Zhang, Yuankai Shi, Xiaohong Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1032221/full |
Similar Items
-
Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01) -
Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
by: Ni Zhao, et al.
Published: (2022-08-01) -
Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
by: Ni Zhao, et al.
Published: (2022-12-01) -
Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
by: Jingting Wang, et al.
Published: (2024-01-01) -
Advances in Predictive Research of Immune Checkpoint Inhibitors-related
Adverse Events
by: Jing ZHANG, et al.
Published: (2023-10-01)